These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 8020714)

  • 21. A simple inhibitor screen is more sensitive than a Bethesda assay in monitoring for the development of inhibitors in haemophilia A and B.
    Keeling D; Beavis J; Sukhu K
    Br J Haematol; 2005 Mar; 128(6):885. PubMed ID: 15755295
    [No Abstract]   [Full Text] [Related]  

  • 22. Jaundice and antibodies directed against factors 8 and 9 in patients treated for haemophilia or Christmas disease in the United Kingdom.
    Biggs R
    Br J Haematol; 1974 Mar; 26(3):313-29. PubMed ID: 4852608
    [No Abstract]   [Full Text] [Related]  

  • 23. Regimens of factor VIII administration--continuous infusion vs. bolus.
    Berntorp E
    Haematologica; 2000 Oct; 85(10 Suppl):69-71; discussion 71-2. PubMed ID: 11187875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.
    Mahasandana C; Patharathienskul D; Suvatte V
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():106-12. PubMed ID: 7886549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T-cell alterations in hemophiliacs treated with commercial clotting factor concentrates.
    Lechner K; Niessner H; Bettelheim P; Deutsch E; Fasching I; Fuhrmann M; Hinterberger W; Korninger C; Neumann E; Liszka K
    Thromb Haemost; 1983 Aug; 50(2):552-6. PubMed ID: 6314582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program.
    Owaidah T; Momen AA; Alzahrani H; Almusa A; Alkasim F; Tarawah A; Nouno RA; Batniji FA; Alothman F; Alomari A; Abu-Herbish S; Abu-Riash M; Siddiqui K; Ahmed M; Mohamed SY; Saleh M
    Medicine (Baltimore); 2017 Jan; 96(2):e5456. PubMed ID: 28079788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hemophiliacs with inhibitor. Experience at the Center of Medical Action for Hemophilia of the S. José Hospital].
    Diniz MJ; Dias Francisco F; Tavares ML; Leal I
    Acta Med Port; 1992 Apr; 5(4):178-80. PubMed ID: 1605065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overview of inhibitors.
    Astermark J
    Semin Hematol; 2006 Apr; 43(2 Suppl 4):S3-7. PubMed ID: 16690373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequency of specific coagulation inhibitors and antiphospholipid antibodies in Tunisian haemophiliacs.
    Kraiem I; Hadhri S; El Omri H; Sassi R; Chaabani W; Ennabli S; Skouri H
    Ann Biol Clin (Paris); 2012; 70(6):659-65. PubMed ID: 23207810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transfusion support for haemophiliacs.
    Allain JP
    Clin Haematol; 1984 Feb; 13(1):99-117. PubMed ID: 6426835
    [No Abstract]   [Full Text] [Related]  

  • 32. [Prophylaxis in patients with haemophilia complicated by inhibitors].
    Paweł Ł
    Pol Merkur Lekarski; 2011 Mar; 30(177):211-4. PubMed ID: 21545000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitor development in patients with hemophilia: an overview.
    Leissinger CA
    Semin Hematol; 2006 Apr; 43(2 Suppl 4):S1-2. PubMed ID: 16690370
    [No Abstract]   [Full Text] [Related]  

  • 34. A genetic view on the etiology of the inhibitor complication.
    Giannelli F; Green PM; Naylor JA
    Blood; 1996 Mar; 87(6):2612. PubMed ID: 8630434
    [No Abstract]   [Full Text] [Related]  

  • 35. The role of genetics in inhibitor formation.
    Gill JC
    Thromb Haemost; 1999 Aug; 82(2):500-4. PubMed ID: 10605742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of allogeneic cytotoxic activity by factor VIII or IX concentrates.
    Soria AG; Bouzas MB; Anselmo A; Ruibal-Ares BH
    Haematologica; 1991; 76(1):33-7. PubMed ID: 1829058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The German National Immune Tolerance Registry, 1997 update. Study Group of German Haemophilia Centres.
    Lenk H
    Vox Sang; 1999; 77 Suppl 1():28-30. PubMed ID: 10529683
    [No Abstract]   [Full Text] [Related]  

  • 38. Switching haemophilia products and inhibitor risk: a United States' perspective.
    Nance D; Rodgers GM
    Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

  • 40. The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis.
    DiMichele D; Kroner B;
    Haematologica; 2000 Oct; 85(10 Suppl):40-2; discussion 42-4. PubMed ID: 11187869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.